Free shipping on all orders over $ 500

Relugolix

Cat. No. M9197
Relugolix Structure
Synonym:

Orgovyx; TAK-385; RVT-601

Size Price Availability Quantity
5mg USD 85  USD85 In stock
10mg USD 135  USD135 In stock
50mg USD 380  USD380 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Relugolix (TAK-385) possesses higher affinity and potent antagonistic activity for human (binding IC50=0.33 nM in the presence of serum) and monkey GnRH receptor (IC50=0.32 nM), but has low affinity for the rat GnRH receptor (IC50=9800 nM).

Relugolix (TAK-385) acts as an antagonist for human GnRH receptor in vivo and daily oral administration potently, continuously and reversibly suppresses the hypothalamic-pituitary-gonadal axis.

Protocol (for reference only)
Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time
Animal Experiment
Animal models Six-week-old male hGNRHR-knock-in mice
Formulation 0.5% methylcellulose solution containing 6 mg/mL citric acid monohydrate
Dosages 3, 10 or 30 mg/kg
Administration oral
Chemical Information
Molecular Weight 623.63
Formula C29H27F2N7O5S
CAS Number 737789-87-6
Solubility (25°C) DMSO: ≥ 48 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] MacLean DB, et al. J Clin Endocrinol Metab. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.

[2] Nakata D, et al. Eur J Pharmacol. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice.

Related LHRH/GnRH Products
Kisspeptin-54(human)

Kisspeptin-54(human) (Metastin(human)) is an endogenous ligand for kisspeptin receptor (KISS1, GPR54).

Luteinizing Hormone Releasing Hormone (LH-RH), salmon

Luteinizing Hormone Releasing Hormone (LH-RH), salmon (Salmon GnRH) is the hypophysiotropic decapeptide synthesized in the hypothalamus that plays a crucial role in the control of reproductive functions.

Phoenixin-14

Phoenixin-14 (PNX-14) is one of the endogenous active isoform, and generates anxiolytic effect via the activation of the AHA GnRH system in mice.

LGnRH-III, lamprey

LGnRH-III, lamprey, an isoform of GnRH isolated from the sea lamprey, is a weak GnRH agonist with antitumor activities.

(D-Trp6)-LHRH free acid

(D-Trp6)-LHRH free acid is a luteinizing hormone-releasing hormone (LHRH) agonist.

  Catalog
Abmole Inhibitor Catalog




Keywords: Relugolix, Orgovyx; TAK-385; RVT-601 supplier, LHRH/GnRH, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.